ATE533490T1 - 4-phenylamino-chinazolin-6-yl-amide - Google Patents

4-phenylamino-chinazolin-6-yl-amide

Info

Publication number
ATE533490T1
ATE533490T1 AT05732761T AT05732761T ATE533490T1 AT E533490 T1 ATE533490 T1 AT E533490T1 AT 05732761 T AT05732761 T AT 05732761T AT 05732761 T AT05732761 T AT 05732761T AT E533490 T1 ATE533490 T1 AT E533490T1
Authority
AT
Austria
Prior art keywords
quinazoline
phenylamino
amide
Prior art date
Application number
AT05732761T
Other languages
German (de)
English (en)
Inventor
Stephen Fakhoury
Helen Lee
Jessica REED
Kevin SCHLOSSER
Karen Sexton
Haile Tecle
Roy Winters
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE533490(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE533490T1 publication Critical patent/ATE533490T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05732761T 2004-05-06 2005-04-25 4-phenylamino-chinazolin-6-yl-amide ATE533490T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56887204P 2004-05-06 2004-05-06
PCT/IB2005/001139 WO2005107758A1 (en) 2004-05-06 2005-04-25 4-phenylamino-quinazolin-6-yl-amides

Publications (1)

Publication Number Publication Date
ATE533490T1 true ATE533490T1 (de) 2011-12-15

Family

ID=34965519

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05732761T ATE533490T1 (de) 2004-05-06 2005-04-25 4-phenylamino-chinazolin-6-yl-amide

Country Status (47)

Country Link
US (3) US7772243B2 (enExample)
EP (1) EP1746999B1 (enExample)
JP (2) JP4205757B2 (enExample)
KR (2) KR20080095915A (enExample)
CN (1) CN1972688B (enExample)
AP (1) AP2204A (enExample)
AR (1) AR048652A1 (enExample)
AT (1) ATE533490T1 (enExample)
AU (1) AU2005239878B9 (enExample)
BE (1) BE2019C540I2 (enExample)
BR (1) BRPI0510604B8 (enExample)
CA (1) CA2565812C (enExample)
CR (1) CR8727A (enExample)
CY (2) CY1112127T1 (enExample)
DK (1) DK1746999T3 (enExample)
EA (1) EA011237B1 (enExample)
EC (1) ECSP066976A (enExample)
ES (1) ES2374553T3 (enExample)
FR (1) FR19C1052I2 (enExample)
GE (1) GEP20084551B (enExample)
GT (1) GT200500103A (enExample)
HN (1) HN2005000192A (enExample)
HR (1) HRP20110958T1 (enExample)
HU (1) HUS1900039I1 (enExample)
IL (1) IL178822A (enExample)
LT (1) LTC1746999I2 (enExample)
LU (1) LUC00127I2 (enExample)
MA (1) MA28632B1 (enExample)
ME (1) ME01267B (enExample)
MX (1) MXPA06012756A (enExample)
MY (1) MY143566A (enExample)
NI (1) NI200600262A (enExample)
NL (2) NL1028967C2 (enExample)
NO (2) NO339692B1 (enExample)
NZ (1) NZ550796A (enExample)
PA (1) PA8631901A1 (enExample)
PE (1) PE20060215A1 (enExample)
PL (1) PL1746999T3 (enExample)
PT (1) PT1746999E (enExample)
RS (1) RS52119B (enExample)
SI (1) SI1746999T1 (enExample)
TN (1) TNSN06360A1 (enExample)
TW (1) TWI334865B (enExample)
UA (1) UA85706C2 (enExample)
UY (1) UY28885A1 (enExample)
WO (1) WO2005107758A1 (enExample)
ZA (1) ZA200609012B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1746999E (pt) * 2004-05-06 2012-01-11 Warner Lambert Co 4-fenilamino-quinazolin-6-il-amidas
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
KR100929146B1 (ko) 2006-06-28 2009-12-01 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체
KR20110130468A (ko) 2009-03-11 2011-12-05 오클랜드 유니서비시즈 리미티드 키나아제 억제제의 프로드럭 형태 및 치료법에서의 이들의 용도
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
CN102382065B (zh) * 2010-08-30 2014-05-28 山东轩竹医药科技有限公司 苯胺取代的喹唑啉衍生物
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
CN102452989B (zh) * 2010-10-19 2014-10-22 山东轩竹医药科技有限公司 苯胺取代的喹唑啉衍生物
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
JP5859118B2 (ja) * 2011-05-26 2016-02-10 山東軒竹医薬科技有限公司 チロシンキナーゼ阻害剤としてのキナゾリン誘導体、その調製方法及びその使用
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
KR20140093223A (ko) * 2011-10-12 2014-07-25 텔리진 엘티디. 키나제 억제제로서의 퀴나졸린 유도체 및 이의 사용 방법
UA111010C2 (uk) 2012-01-17 2016-03-10 Астеллас Фарма Інк. Сполука піразинкарбоксаміду
CN104350049B (zh) 2012-05-07 2016-07-13 苏州韬略生物科技有限公司 作为激酶抑制剂的取代氨基喹唑啉
US9556191B2 (en) 2013-04-28 2017-01-31 Sunshine Lake Pharma Co., Ltd. Aminoquinazoline derivatives and their salts and methods of use thereof
CN103288759B (zh) * 2013-05-16 2015-05-20 苏州明锐医药科技有限公司 达克米替尼的制备方法
CN103288758B (zh) * 2013-05-16 2015-01-21 苏州明锐医药科技有限公司 一种达克米替尼的制备方法
CN105408334B (zh) 2013-05-21 2017-10-10 江苏迈度药物研发有限公司 作为激酶抑制剂的取代的吡唑并嘧啶类化合物
CN103304492B (zh) * 2013-06-20 2015-12-23 湖南欧亚生物有限公司 一种EGFR抑制剂Dacomitinib的合成方法
EP3022186B1 (en) * 2013-07-18 2020-02-26 Shanghai Fochon Pharmaceutical Co. Ltd Quinazoline derivatives, compositions thereof, and use as pharmaceuticals
CN105859641B (zh) * 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
US20190016689A1 (en) * 2016-01-06 2019-01-17 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
CN107721986A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721987A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107721985A (zh) * 2016-08-12 2018-02-23 山东轩竹医药科技有限公司 喹唑啉类酪氨酸激酶抑制剂的晶型
CN107793368B (zh) * 2016-08-31 2021-10-15 四川科伦药物研究院有限公司 达可替尼溶剂化物、其新晶型及其制备方法和用途
KR102213040B1 (ko) * 2017-12-20 2021-02-05 한국원자력의학원 방사선 손상 보호 또는 완화, 및 폐섬유화 예방 또는 치료 용도
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
MX2021003517A (es) 2018-09-25 2021-08-16 Black Diamond Therapeutics Inc Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
US12465608B2 (en) 2019-03-29 2025-11-11 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
MX2022001952A (es) 2019-08-15 2022-06-02 Black Diamond Therapeutics Inc Compuestos de alquinil quinazolina.
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN113045541A (zh) * 2019-12-27 2021-06-29 广东东阳光药业有限公司 Egfr抑制剂新晶型及其制备方法
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN113717111A (zh) * 2020-05-25 2021-11-30 苏州晶云药物科技股份有限公司 喹唑啉类化合物的晶型及其制备方法
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
WO2022010537A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Gas41 inhibitors and methods of use thereof
CN112707869B (zh) * 2020-12-25 2022-03-22 扬子江药业集团有限公司 一种达可替尼杂质及其制备方法
WO2023187037A1 (en) 2022-03-31 2023-10-05 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
KR20250006237A (ko) 2022-04-28 2025-01-10 아스트라제네카 아베 축합 바이사이클릭 헤테로방향족 화합물 및 암의 치료에서의 이의 용도
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
WO1993003034A1 (en) 1991-07-29 1993-02-18 Warner-Lambert Company Quinazoline derivatives as acetylcholinesterase inhibitors
RU2117664C1 (ru) 1991-08-22 1998-08-20 Варнер-Ламберт Компани Производные тетразолсодержащего амида, смесь их изомеров, отдельные изомеры или фармацевтически приемлемые соли
US5366987A (en) 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5412714A (en) * 1992-02-24 1995-05-02 At&T Corp. Mnemonic and synonymic addressing in a telecommunications system
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
CA2183655C (en) 1994-02-23 2001-03-06 Lee D. Arnold 4-polycyclic amino-substituted quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (enExample) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE69613367T2 (de) 1995-04-27 2002-04-18 Astrazeneca Ab, Soedertaelje Chinazolin derivate
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JPH11514361A (ja) 1995-10-16 1999-12-07 藤沢薬品工業株式会社 Ｈ＋−ＡＴＰａｓｅとしての複素環式化合物
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
CZ295468B6 (cs) 1996-04-12 2005-08-17 Warner-Lambert Company Polycyklické sloučeniny
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
CO4940469A1 (es) 1997-03-05 2000-07-24 Sugen Inc Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5929080A (en) 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
PT980244E (pt) 1997-05-06 2003-10-31 Wyeth Corp Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CA2333392A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
TW533204B (en) 1998-07-30 2003-05-21 Wyeth Corp A process for preparing substituted quinazoline derivatives
US6384223B1 (en) 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP2896612A1 (en) 1998-09-29 2015-07-22 Wyeth Holdings LLC Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
NZ512189A (en) 1998-11-19 2003-10-31 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4- yl-propoxy)-quinazolin-6-yl]-acrylamide useful as an irreversible inhibitor of tyrosine kinases
CN1341104A (zh) 1999-02-27 2002-03-20 贝林格尔英格海姆法玛公司 具有对因酪氨酸激酶引起的信号转导有抑止作用的4′－氨基喹唑啉及喹啉衍生物
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
EP1194418A1 (de) * 1999-06-21 2002-04-10 Boehringer Ingelheim Pharma KG Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AUPQ113799A0 (en) * 1999-06-22 1999-07-15 University Of Queensland, The A method and device for measuring lymphoedema
EP1202746B1 (en) 1999-08-12 2006-10-04 Wyeth Holdings Corporation Nsaid and egfr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
KR20020032608A (ko) 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 화합물 및 이를 함유하는 제약 조성물
US6664390B2 (en) 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
EP1274692B1 (en) 2000-04-07 2006-08-02 AstraZeneca AB Quinazoline compounds
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE50111799D1 (de) * 2000-04-08 2007-02-15 Boehringer Ingelheim Pharma Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
DE10031971A1 (de) 2000-06-30 2002-01-10 Goedecke Ag Polymorphe Formen/Hydrate von N-[4-(3-Chlor-4-fluor-phenylamino)-7-(3-morpholin-4-yl-propoxy)-chinazolin-6-yl]-acrylamid Dihydrochlorid, Verfahren zu ihrer Herstellung sowie die Verwendung derselben zur Herstellung von Medikamenten mit irreversibler Tyrosinkinasehemmwirkung
US6446671B2 (en) * 2000-08-04 2002-09-10 John G. Armenia Double wall safety hose
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6653305B2 (en) 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US20020082270A1 (en) 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
JP3712393B2 (ja) 2000-10-20 2005-11-02 エーザイ株式会社 含窒素芳香環誘導体
US20030158196A1 (en) 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
CA2442742A1 (en) 2001-02-21 2002-08-29 Mitsubishi Pharma Corporation Quinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
GB0118752D0 (en) 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
WO2003040108A1 (en) 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
WO2003045939A1 (en) 2001-11-30 2003-06-05 Pfizer Products Inc. Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
EA200400680A1 (ru) 2001-12-12 2005-06-30 Пфайзер Продактс Инк. Производные хиназолина для лечения аномального роста клеток
DK1463506T3 (da) 2001-12-24 2010-01-11 Astrazeneca Ab Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
BRPI0307786B8 (pt) 2002-02-26 2021-05-25 Astrazeneca Ab composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10217689A1 (de) * 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20040048887A1 (en) 2002-07-09 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
PA8578001A1 (es) 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
CA2514479A1 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CA2521348A1 (en) 2003-04-09 2004-10-21 Pfizer Products Inc. Processes for the preparation of n-((((pyridinyloxy)-phenylamino) quinazolinyl)-allyl) acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
MXPA05011076A (es) 2003-04-16 2006-01-24 Astrazeneca Ab Derivados de quinazolina para el tratamiento de cancer.
JP2007502807A (ja) 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Ｅｒｂｂ２抗がん剤の投与スケジュール
WO2005040125A1 (en) 2003-10-06 2005-05-06 Gpc Biotech Ag Quinazoline derivatives for the treatment of herpesviral infections
EP1690856A4 (en) 2003-11-28 2007-09-05 Aveo Pharmaceuticals Inc CHINAZOLINE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF
PT1746999E (pt) * 2004-05-06 2012-01-11 Warner Lambert Co 4-fenilamino-quinazolin-6-il-amidas

Also Published As

Publication number Publication date
HK1106432A1 (en) 2008-03-14
AR048652A1 (es) 2006-05-10
NI200600262A (es) 2008-03-07
BE2019C540I2 (enExample) 2024-08-08
JP4966923B2 (ja) 2012-07-04
CN1972688A (zh) 2007-05-30
IL178822A (en) 2013-07-31
US8623883B2 (en) 2014-01-07
AU2005239878A1 (en) 2005-11-17
EA200601849A1 (ru) 2007-04-27
LUC00127I1 (fr) 2019-09-19
NL1028967C2 (nl) 2006-06-27
PE20060215A1 (es) 2006-03-20
CR8727A (es) 2006-11-30
AP2006003810A0 (en) 2006-12-31
US20100190977A1 (en) 2010-07-29
BRPI0510604B8 (pt) 2021-05-25
CY2019034I2 (el) 2019-11-27
MXPA06012756A (es) 2007-01-16
AU2005239878B9 (en) 2010-01-07
SI1746999T1 (sl) 2012-01-31
LTC1746999I2 (lt) 2020-05-11
EP1746999B1 (en) 2011-11-16
UY28885A1 (es) 2005-12-30
PA8631901A1 (es) 2005-11-25
TW200540163A (en) 2005-12-16
IL178822A0 (en) 2007-03-08
ES2374553T3 (es) 2012-02-17
RS52119B (sr) 2012-08-31
EP1746999A1 (en) 2007-01-31
CY1112127T1 (el) 2015-11-04
EA011237B1 (ru) 2009-02-27
US8466165B2 (en) 2013-06-18
WO2005107758A1 (en) 2005-11-17
NL1028967A1 (nl) 2005-11-08
HRP20110958T1 (hr) 2012-01-31
FR19C1052I1 (enExample) 2019-10-11
PL1746999T3 (pl) 2012-07-31
JP2007536368A (ja) 2007-12-13
CY2019034I1 (el) 2019-11-27
KR20080095915A (ko) 2008-10-29
UA85706C2 (xx) 2009-02-25
US20050250761A1 (en) 2005-11-10
LUC00127I2 (fr) 2020-10-06
PT1746999E (pt) 2012-01-11
ZA200609012B (en) 2008-06-25
NO20065626L (no) 2007-01-23
FR19C1052I2 (fr) 2020-09-04
NO339692B1 (no) 2017-01-23
BRPI0510604B1 (pt) 2020-05-12
CA2565812C (en) 2012-03-13
JP2009007363A (ja) 2009-01-15
AU2005239878B2 (en) 2009-09-03
LTPA2019016I1 (lt) 2019-09-25
NO2019035I1 (no) 2019-09-13
MY143566A (en) 2011-05-31
TNSN06360A1 (fr) 2008-02-22
NL301004I2 (nl) 2026-01-21
GT200500103A (es) 2006-01-10
NZ550796A (en) 2010-07-30
US20130274275A1 (en) 2013-10-17
CN1972688B (zh) 2012-06-27
GEP20084551B (en) 2008-11-25
KR20070008683A (ko) 2007-01-17
DK1746999T3 (da) 2012-01-23
TWI334865B (en) 2010-12-21
HUS1900039I1 (hu) 2019-10-28
CA2565812A1 (en) 2005-11-17
JP4205757B2 (ja) 2009-01-07
AP2204A (en) 2011-02-07
MA28632B1 (fr) 2007-06-01
ECSP066976A (es) 2006-12-29
US7772243B2 (en) 2010-08-10
KR100885835B1 (ko) 2009-02-26
BRPI0510604A (pt) 2007-10-30
ME01267B (me) 2013-06-20
HN2005000192A (es) 2010-06-09

Similar Documents

Publication Publication Date Title
CY2019034I2 (el) 4-φαινυλαμινο-κιναζολιν-6-υλ-αμιδια
DE502005005116D1 (de) Wischblatt
DE502005005035D1 (de) Wischblatt
DE502005005628D1 (de) Wischblatt
DE112005001624A5 (de) Brillengestell
ATE520680T1 (de) Hiv-hemmende 5-heterocyclylpyrimidine
ATE392425T1 (de) Thiazolyl-dihydro-indazole
DE502005004843D1 (de) Einspritzventil
ATE459633T1 (de) Makrolide
DE502005004842D1 (de) Wischblatt
DE502005006395D1 (de) Verschlusskappe
DE502005005991D1 (de) Sensorleuchte
DE112005000809A5 (de) Wankstabilisierungseinrichtung
DE502005007739D1 (de) Kranballastierungssystem
DE502005008587D1 (de) Kugelgelenk
DE502004012213D1 (de) Flachdichtung
DE202004017327U1 (de) Fitnessrad
DE502005007584D1 (de) Raftfahrzeuge
DE502005007637D1 (de) Flachdichtung
DE502005002602D1 (de) Fahrzeugtemperiersystem
DE502005004695D1 (de) Sicherheitsfangseil
AT500198B1 (de) Ladewagen
DE112005000794T5 (de) Urethanspritzpistolenanordnung
DE502005007997D1 (de) Aftfahrzeug
ATE389633T1 (de) Omega-phenyloctanamide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1746999

Country of ref document: EP